ProofPilot Announces Series C Funding
ProofPilot Announces Series C Funding
NEW YORK, July 11, 2024 /PRNewswire/ -- ProofPilot, a leading Clinical Experience Platform (CXP), announced the closing of its Series C financing, led by Sopris Capital with Mitsui & Co. (U.S.A.), Inc. participating.
美国纽约，2024年7月11日 /美通社/ -- ProofPilot, 一家著名的临床体验平台（CXP）宣布完成了C轮融资，由Sopris Capital领投，Mitsui & Co. (美国) Inc. 参投。
"Much of the focus in clinical trial technology has been on data capture and AI, but supporting the clinical trial experience for stakeholders has taken a backseat," said Chris Venezia, CEO of ProofPilot. "Our strategic advisory board, comprising patients, research sites, and sponsors, is solving the right challenges and needs to modernize experiences for all stakeholders. This repeat investment from our Series B investors recognizes the market's need and provides us with resources to scale and accelerate life-saving therapies."
ProofPilot的CEO Chris Venezia表示："在临床试验技术领域，大部分的关注都集中在数据采集和人工智能上，而为相关利益相关者提供支持则被忽视了。我们的战略顾问委员会由病患、研究机构和赞助商组成，正在解决正确的挑战和需求，以实现对所有利益相关者体验的现代化。我们的B轮投资者再次投资反映了市场需求，并为我们提供了规模化和加速拯救生命疗法的资源。"
ProofPilot's platform, StudyCoPilot, centralizes and simplifies communication for sponsors, patients, and sites across the clinical trial experience. The products and services support key initiatives like improving DE&I, streamlining recruitment & retention, and easing site burden. ProofPilot has scaled its capabilities for enterprise use and has industry leading pharmaceutical clients deploying StudyCoPilot globally.
ProofPilot的平台StudyCoPilot集中和简化赞助商、病患和研究机构在临床试验体验期间的沟通。该产品与服务支持改善多元文化、简化招募与留存以及减轻研究机构的负担等关键计划。ProofPilot已将其能力应用于企业用户，并拥有全球领先的药品客户在全球部署StudyCoPilot。
"The sky is the limit with ProofPilot, and we are excited about investing in the company. We have tremendous confidence in the team and are proud to see some of the world's leading life sciences companies adopt the technology," said Abinav Sankar, Partner at Sopris Capital.
Sopris Capital合伙人Abinav Sankar表示："ProofPilot的发展前景无限，我们很高兴投资此公司。我们对团队有极大信心，并很自豪地看到世界领先的生命科学公司采用此技术。"
About ProofPilot
关于ProofPilot
ProofPilot enhances clinical trials with its Clinical Experience Platform (CXP). The StudyCoPilot platform centralizes and simplifies communication for sponsors, patients, and sites across the clinical trial experience. Learn more at: .
ProofPilot通过其临床体验平台（CXP）增强临床试验。StudyCoPilot平台集中和简化赞助商、病患和研究机构在临床试验体验期间的沟通。了解更多：。
About Sopris Capital
关于Sopris Capital
Sopris Capital invests growth equity in technology-enabled business services and SaaS companies solving critical pain points. Sopris partners with fast-growing companies with a validated business model, proven product/market fit, and a strong management team. Learn more at: .
Sopris Capital在为解决关键痛点的技术业务服务和SaaS公司中进行增长股权投资。Sopris与具有验证的商业模式、证明的产品/市场适配度和强大的管理团队的快速增长公司合作。了解更多：。
About Mitsui
关于三井
Mitsui & Co. (U.S.A.), Inc. ("Mitsui USA"), a subsidiary of Mitsui & Co., Ltd., Tokyo, Japan, is one of the most diversified trading, investment, and service enterprises globally. Mitsui & Co. pursues "360° business innovation" across product sales, logistics, financing, and major international infrastructure projects. More information on Mitsui USA can be found at .
三井洲(美国)有限公司(Mitsui & Co. (U.S.A.), Inc.)是日本三井株式会社(Mitsui & Co., Ltd., Tokyo, Japan)旗下的子公司之一，是全球最多元化的贸易、投资和服务企业之一。三井株式会社在产品销售、物流、融资和大型国际基础设施项目方面追求"360°商业创新"。有关Mitsui USA的更多信息，请访问 。
Media Contacts: Colleen Yang, [email protected]
媒体联系人：Colleen Yang, [email protected]
SOURCE ProofPilot
来源：ProofPilot